867065-53-0

Basic information

• Product Name: Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate
• Synonyms: Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate;tert-butyl 4-(4-(ethoxycarbonyl)thiazol-2-yl)piperazine-1-carboxylate;4-(4-Ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic acid tert-butyl ester;ethyl 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1,3-thiazole-4-carboxylate
• CAS NO: 867065-53-0
• Molecular Formula: C15H23N3O4S
• Molecular Weight: 341.43
• Mol File: 867065-53-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 455.525°C at 760 mmHg
• Flash Point: 229.293°C
• Appearance: /
• Density: 1.232g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate(867065-53-0)
• EPA Substance Registry System: Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate(867065-53-0)

Safety Data

• Hazardous Substances Data: 867065-53-0(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate is a complex organic compound that contains a variety of functional groups, including an ester group, a piperazine ring, a thiazole ring, and a carbamate group. Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate is known for its role in organic synthesis, serving as a valuable intermediate in the preparation of a variety of substances. Its exact physical and chemical properties, such as its melting point, boiling point, and solubility, can vary based on factors such as purity and temperature, but in general it is a stable compound that requires specific conditions to react. As with many organic chemicals, care must be taken to handle this compound safely due to its potential reactivity and the possible production of harmful fumes or byproducts.

InChI:InChI=1/C15H23N3O4S/c1-5-21-12(19)11-10-23-13(16-11)17-6-8-18(9-7-17)14(20)22-15(2,3)4/h10H,5-9H2,1-4H3

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 70-23-5 ethyl Bromopyruvate 
• 196811-66-2 4-(tert-butoxycarbonyl)piperazine-1-thiocarboxamide 
• 81449-93-6 ethyl 2-chloro-thiazole-5-carboxylate 
• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 
• 41731-52-6 2-chloro-thiazole-4-carboxylic acid ethyl ester 

Downstream Products

• 922516-49-2 ethyl 2-(1-piperazinyl)-4-thiazolecarboxylate monohydrochloride 
• 105653-53-0 ethyl 2-(piperazin-1-yl)thiazole-4-carboxylate hydrochloride 
• 668484-45-5 2-(4-[(tert-butoxy)carbonyl]piperazin-1-yl)-1,3-thiazole-4-carboxylic acid 
• 1037793-23-9 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Chemo-selective syntheses of: N-t -boc-protected amino ester analogs through Buchwald-Hartwig amination

The synthesis of N-protected amino esters is achieved via a chemo-selective Buchwald Hartwig cross-coupling reaction using PEPPSI-IPr Pd-catalyst. Nearly two dozen functionally and structurally diverse amino ester molecules are created by individually cross-coupling eight aryl halo esters and three different secondary amines. We observed that product formation is more facile in those heterocyclic esters where nitrogen is present ortho to the halo substituent in the heteroaromatic ring. Based on this observation, we propose a possible intermediate step in the cross-coupling cycle, where the nitrogen electron lone pair in the heterocycle may play an important role leading to a higher reaction yield.

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS

Use of oxymethylene aryl GPRl 19 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provide